
ANIMA Megatrend People - Class F

ANIMA

Marketing communication for Professional Clients and Qualified Investors only. ANIMA SGR S.p.A. acting as management company on behalf of ANIMA Funds plc, an Irish open-ended Investment Company with variable capital (SICAV) – UCITS This document should be read in conjunction with the Prospectus and the KID, which are available at ANIMA Headquarters, third party distributors and on our corporate website www.animasgr.it.

All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.



Fund Facts	
Asset Class	Global Equity
Fund's Inception	08 July 2019
Fund Base Currency	EUR
Fund Size (EUR mln)	869
Benchmark	95% MSCI AC World – EUR 5% ICE BofA EUR Treasury Bill
Domicile	Italy
Fund Type	UCITS
ISIN	IT0005376220
Bloomberg Ticker	ANMGTRF IM EQUITY
Distribution Policy	Accumulation
SFDR	Art. 8
Max Initial Charge	Up to 3%
Exit Fee	None
Ongoing Charges (2024)	0.99%
Management Fee	0.86%
Performance Fee	20% o/perf vs Bmk
Settlement	T+3
Liquidity / NAV Calculation Minimum Initial Investment	Daily
	EUR 1,000,000
Portfolio Manager	
Claudia Collu	Lead PM

Historical Data & Statistic	S	
Historical Perfomances	Fund	Benchmark
1M	-4.1%	-3.9%
3M	-13.8%	-11.3%
6M	-5.8%	-3.4%
1Y	2.6%	5.2%
3Y (Annualized)	6.6%	7.3%
STD (Annualized)	9.6%	9.3%
Statistics - Last 3Y Ann.	Fund	Benchmark
Volatility	14.5%	13.4%
Return/Volatility	0.46	0.55
TEV	3.5%	-
Information Ratio	-0.21	-
Beta	1.05	
Calendar Years	Fund	Benchmark
YTD	-10.8%	-8.8%
2024	26.0%	24.2%
2023	16.9%	17.3%
2022	-14.5%	-12.4%
2021	31.6%	26.0%

The performances quoted represents past performances. Past performances/prices are not a reliable indicator of future performances/prices. This is an advertising document and is not intended to constitute investment advice.



Monthly Fund Manager's comment

In April, the MSCI AC World Index recorded a performance of -4.28%, due to tariff news driving significant market volatility following the anticipated "Liberation Day," which, contrary to expectations, had not significantly reduced uncertainty. Instead, it appeared to be a potential starting point for negotiations rather than a definitive clearing event. In the first week of April, the S&P 500 declined by approximately 13%. Equities continued to experience strong fluctuations throughout the month, to nearly return to pre-liberation day levels, as the Trump administration's shift towards a more conciliatory approach has succeeded in stabilizing the markets and providing support. The transition to a softer approach followed the notable movements observed in the bond and currency markets, which caused investor concerns: long-dated Treasuries – contradicting the "flight to safety rhetoric" - sold off and the dollar fell against every G7 currency, calling into question its status as a safe-haven currency. Sector-wise, the rotation toward defensive global sectors continued in April. Software performed best, while consumer staples, utilities and telecom also outperformed. In contrast, healthcare underperformed the broader market, and energy was the worst performing sector, as the oil price fell -17.9%.

During the month, the fund underperformed its benchmark by 22 basis points, resulting in a negative return of -4.1%. Despite Megatrend's structural overweight to the US market – that has underperformed - we were able to mitigate the negative impact from allocation by promptly reducing US exposure, mainly in favour of a greater cash component, which in turn provided us with the flexibility to re-enter the market at more attractive valuations. Positioning in the healthcare space has not been rewarding; however, following the recent underperformance, large-cap healthcare now trades at a four-turn discount to the broader S&P. Notably, large-cap pharmaceutical and biotech names appear particularly de-risked. While some tariff-related uncertainty persists, markets seem to have moved beyond the peak of tariff shocks. Combined with ongoing concerns around potentially underappreciated recession risks, this environment strengthens the investment case for the pharmaceutical segment. We remain constructive on the obesity market, as oral GLP-1 therapies for obesity represent one of the most promising new product cycles in the broader biopharma space. LLY recently reported positive Phase 3 trial results for Orforglipron, its oral small-molecule GLP-1 treatment for type 2 diabetes. In our view, this materially de-risks the company's oral obesity pipeline and reinforces LLY's leadership position in this rapidly evolving market.

Hyper-scalers confirmed that the AI investment cycle remains firmly intact, with GOOGL/MSFT reiterating spending plans, META raising capex guidance and AMZN highlighting continued capacity constraints. In aggregate, capex for the group grew 62% YoY in 1Q (vs. 68% in 4Q). Although capex growth is set to decelerate throughout the year, hyper-scalers are still expected to grow capex 35% YoY in 2025, far outpacing forecasts for the rest of the index (+6% YoY). Looking forward, we remain cautious as the fundamental backdrop is still uncertain, with a divergence between negative sentiment indicator and stronger hard data, largely due to frontloading. Forward-looking indications Forward-looking indicators suggest that hard data may begin to deteriorate soon. The Fed is also more likely to display a wait-and-see, which may dampen expectations of a dovish "Fed put".

Monthly Exposure Report

Sector Allocation	Fund	Column1	Delta
Information Technology	26.5%	-	4.0%
Health Care	19.1%		9.6%
Financials	16.0%	•	-1.1%
Consumer Discretionary	9.2%	•	-0.9%
Communication Services	8.0%		0.1%
Consumer Staples	7.0%	•	0.9%
Industrials	4.9%	-	-5.2%
Materials	2.1%	•	-1.3%
Utilities	0.7%		-2.0%
Energy	0.0%		-3.5%
Real Estate	0.0%	•	-2.0%

Top 5 Overweight	Fund	Delta
Microsoft	5.3%	1.8%
Eli Lilly & Co	2.5%	1.6%
Bank of America	1.7%	1.4%
Astrazeneca	1.6%	1.3%
Linde	1.6%	1.3%

Top 5 Underweight	Fund	Delta
Taiwan Semiconductor Ma	-	-0.9%
Netflix	-	-0.6%
Exxon Mobil Corporation	-	-0.6%
Tencent Holdings	-	-0.5%
Nestlé	-	-0.3%

Geographical Allocatio	Fund	Column1	Delta
United States	71.4%		11.0%
France	5.2%	-	2.7%
Japan	2.8%	•	-2.0%
United Kingdom	2.5%	•	-0.8%
Switzerland	1.8%		-0.3%
Germany	1.8%	•	-0.5%
Italy	1.7%	•	1.0%
Netherlands	1.3%		0.2%
Corea Del Sud	1.1%		0.1%
China	1.0%	-	-1.9%
Others	3.0%		-11.0%

Characteristics	Fund	Benchmark
Active Share	60.2%	-
Number of Holdings	95	2558
Top 5 Holdings as % of Total	20.6%	19.4%
Top 10 Holdings as % of Total	30.5%	29.2%
Top 15 Holdings as % of Total	38.0%	36.7%
Dividend Yield	2.4%	2.0%
Percentage of Cash	6.4%	-
Rating ESG	B-	-

Data as of 30/04/2025

The performances quoted represents past performances. Past performances/prices are not a reliable indicator of future performances/prices. This is an advertising document and is not intended to constitute investment advice.





The historical data used to calculate the synthetic risk indicator cannot provide a reliable indication about the future risk profile of the Fund.

Important Information

This is a marketing communication. This marketing communication is issued by ANIMA SGR S.p.A. (the "Manager"), an Italian asset management company authorized & regulated by the Bank of Italy. The Manager is part of the ANIMA Holding S.p.A. Group.

The Manager, or any other company part of ANIMA Holding S.p.A. Group, makes no representation or warranty that the information contained herein is accurate, current, complete, fair or correct or that any transaction is appropriate for any person and it should not be relied on as such. The Manager, and any other company part of ANIMA Holding S.p.A. Group, accepts no liability for any direct, indirect, incidental or consequential damages or losses arising from the use of this report or its content. This document is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal.

This communication is intended for institutional, professional, qualified or sophisticated investors as defined by any applicable local laws and regulations, exclusively in the countries as defined in this present document (all such investors being referred to as "Relevant Persons"). This document is not intended for general public, private customers, retail investors and U.S. Persons, as defined by "Regulation S" of the Securities and Exchange Commission by virtue of the US Securities Act of 1933.

In particular, any Relevant Person should be: (i) with regard to European Union, a "Professional" investor as defined in Directive 2014/65/EU dated 15 May 2014 on markets in financial instruments ("MiFID"), as further amended, and as the case may be in each local regulations; (ii) with regard to Switzerland, a "Qualified Investor" within the meaning of the provisions of the Collective Investment Schemes Act dated 23 June 2006 (CISA), as implemented by Collective Investment Schemes Ordinance dated 22 November 2006 (CISO), the Financial Services Act (FinSA) dated 15 June 2018 and the FINMA's Circular of 28 August 2013, no. 2013/09 on distribution of collective investment schemes; (iii) with regard to United Kingdom, a "Professional client" as defined in the Conduct of Business Sourcebook of the Financial Conduct Authority ("FCA") Handbook.

The data and information contained in this document are provided for information purposes only. The information and opinions contained herein do not constitute a recommendation and cannot be considered as investment, legal or tax advice and have no legal or contractual value. The information and opinions contained in this document do not take into account the specific individual circumstances of each investor. The tax treatment depends on the individual circumstances of each investor and may be subject to change in the future. Please contact your financial and tax advisor to ensure the suitability of the product with your personal situation. Before making an investment decision, you must read the Prospectus, the Key Information Document or any applicable local offering document, and in particular the risk factors pertaining to an investment in the Sub-Fund.

The performances quoted represents past performances. Past performances/prices are not a reliable indicator of future performances/prices. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Foreign currency rates of exchange may adversely affect the value, price or income of the financial instruments mentioned in this document if the reference currency of one of these financial instruments is different than the investor's.

MSCI: The information obtained from MSCI included in this marketing document may only be used for your internal use, may not be reproduced or re-disseminated in any form and may not be used to create any financial instruments or products or any indices. The MSCI information and that of other data providers is provided on an 'as is' basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling or creating any MSCI information (collectively, the "MSCI Parties") and other data providers, expressly disclaim all warranties (including, without limitation any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party or other data provider have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages.

S&P 500: product of S&P Dow Jones Indices LLC or its affiliates ("SPDJI"). Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC ("S&P") and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones") and these trademarks have been licensed for use by SPDJI.

Stoxx Europe 600 index and the trademark used in the index name are the intellectual property of STOXX Limited, Zurich, Switzerland and/or its licensors. The index is used under license from STOXX. The securities based on the index is in no way sponsored, endorsed, sold or promoted by STOXX and/or its licensors and neither STOXX nor its licensors shall have any liability with respect thereto.

2025 ANIMA SGR S.p.A (UCITS management company). All rights reserved.

